Contract research, development, and manufacturing organisation Anthem Biosciences shares recorded healthy returns on its market debut on July 21, closing with more than 28 percent gains and valuing at over Rs 41,000 crore.
The stock opened at Rs 723.05 on the NSE, soaring 26.85 percent over the issue price of Rs 570, which was on expected lines. It sustained its opening level throughout session and touched an intraday high of Rs 747, before finishing the session at Rs 730.35, up 28.13 percent with volume of 4.10 crore shares.
On the BSE, too, the stock closed at same price with volume of 39.85 lakh shares.
Anthem Biosciences shares recorded market capitalisation of Rs 41,017 crore at the closing.
The pharma that manufactures and sells specialised fermentation-based active pharmaceutical ingredients (including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars) has raised Rs 3,395 crore via initial share sale last week. The IPO, which comprised of solely offer-for-sale by promoters and investors, saw a massive 63.86 times subscription.
Hence, the entire IPO proceeds were received by the selling shareholders, and the company did not get any offer money. The price band for the offer was Rs 540-570 per share.
Click Here To Read All IPO News
Bengalore-based Anthem is a contract research, development and manufacturing organization (CRDMO) with fully integrated operations including drug discovery, development and manufacturing. Its specialty ingredients business is complementary to CRDMO business.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
